greeksoup/ stock research
Stock research / United States / BMY / Q4 FY2021

Bristol-Myers Squibb (BMY) Q4 FY2021 earnings: revenue $12.0 billion, up 8.3% on the year

Bristol-Myers Squibb Co. (BMY) reported revenue of $12.0 billion for Q4 FY2021, the quarter ended 31 December 2021, up 8.3% on the same quarter a year earlier. Net income was $2.4 billion, and diluted earnings per share $1.07. The figures are the company's own, from the 10-K it filed with the SEC on 9 February 2022.

Revenue
$12.0 billion
+8.3% on the year · +3.1% on the quarter
Q1 FY2020Q4 FY2021
Operating margin
15.5%
-94.4% a year earlier
Q1 FY2020Q4 FY2021
Net income
$2.4 billion
+53.4% on the quarter
Q1 FY2020Q4 FY2021
Diluted EPS
$1.07
+55.1% on the quarter
Q1 FY2020Q4 FY2021

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ millionQ4 FY2021Q3 FY2021Q4 FY2020On the quarterOn the yearLast 8 quarters
Revenue11,98511,62411,068+3.1%+8.3%
Cost of revenue2,356n/an/a
Gross profit9,629n/an/a
Gross margin80.3%n/an/a
Research and development2,607n/an/a
Selling, general and administrative2,354n/an/a
Operating income1,8582,157-10,451-13.9%
Operating margin15.5%18.6%-94.4%
Interest expense323n/an/a
Pre-tax income1,858n/an/a
Income tax-514n/an/a
Effective tax rate-27.7%n/an/a
Net income2,3721,546-10,027+53.4%
Net margin19.8%n/an/a
Diluted EPS$1.07$0.69-$4.45+55.1%
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionQ4 FY2021Q3 FY2021Q4 FY2020On the quarterOn the yearLast 8 quarters
Operating cash flow4,057n/an/a
Capital expenditure320n/an/a
Free cash flow3,737n/an/a
Free cash flow margin31.2%n/an/a
Cash from investing401n/an/a
Cash from financing-3,967n/an/a
Depreciation and amortisation2,6312,7442,690-4.1%-2.2%
Share-based compensation133n/an/a
Buybacks2,751n/an/a
Dividends paid1,099n/an/a
Diluted shares, weighted2,245m2,243mn/a+0.1%
Shares outstanding at period end2,180m2,220m2,240m-1.8%-2.7%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ4 FY2021Q3 FY2021Q4 FY2020On the quarterOn the yearLast 8 quarters
Shareholders' equity35,94637,21337,822-3.4%-5.0%
Non-controlling interest60.0n/an/a
Short-term borrowings4,948n/an/a
Debt44,36944,74250,676-0.8%-12.4%
Operating lease liabilities874n/an/a
Other liabilities23,117n/an/a
Total liabilities and equity109,314n/an/a
Fixed assets6,049n/an/a
Goodwill20,502n/an/a
Intangible assets42,527n/an/a
Investments2,987n/an/a
Cash and equivalents13,97913,54014,546+3.2%-3.9%
Receivables7,979n/an/a
Inventory2,095n/an/a
Other assets13,196n/an/a
Total assets109,314n/an/a

Questions

What was Bristol-Myers Squibb's revenue in Q4 FY2021?

Bristol-Myers Squibb (BMY) reported revenue of $12.0 billion for Q4 FY2021, the quarter ended 31 December 2021, up 8.3% on the same quarter a year earlier.

How much did Bristol-Myers Squibb earn in Q4 FY2021?

Net income for Q4 FY2021 was $2.4 billion, and diluted earnings per share $1.07.

When did Bristol-Myers Squibb report Q4 FY2021 results?

Bristol-Myers Squibb filed its 10-K for the year that ended with the quarter on 9 February 2022; the fourth quarter is the year less the first three.

Quarterly results, the last 20 quarters

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue11,98511,64811,88711,21811,40611,33711,22610,96611,47711,86512,20111,89212,34211,20112,26912,22212,50211,48912,97313,069
Cost of revenue2,3562,4712,7202,3532,5932,5662,8762,5062,7452,9323,2672,9574,8123,0333,3723,4354,0963,4213,7264,146
Gross profit9,6299,1779,1678,8658,8138,7718,3508,4608,7328,9338,9348,9357,5308,1688,8978,7878,4068,0689,2478,923
Gross margin80%79%77%79%77%77%74%77%76%75%73%75%61%73%73%72%67%70%71%68%
R&D2,6072,2602,3212,4182,5102,3212,2582,2422,4782,6952,8992,3743,1912,2572,5802,5282,5862,6492,9592,365
SG&A2,3541,8311,7871,9302,2661,7621,9342,0032,0732,3671,9281,9832,1361,5841,7131,7892,1811,6171,8261,699
Operating income1,8581,6871,9582,2091,8592,7701,8592,1371,674-11,5161,2861,6761752,9711,7733,1141,4703,2394,0862,536
Operating margin16%14%16%20%16%24%17%19%15%-97%11%14%1%27%14%25%12%28%31%19%
Interest expense323326313299294288282280316425521505496494485480432411407403
Pre-tax income1,8581,6871,9582,2091,8592,7701,8592,1371,674-11,5161,2861,6761752,9711,7733,1141,4703,2404,0862,536
Tax rate-28%24%27%27%-9%18%-12%9%-5%n/a-31%28%57%17%26%30%26%17%19%15%
Net income2,3721,2781,4211,6062,0222,2622,0731,9281,762-11,9111,6801,21172.02,4561,3102,2011,0872,6773,3172,162
Net margin20%11%12%14%18%20%18%18%15%-100%14%10%1%22%11%18%9%23%26%17%
Diluted EPS$1.07$0.59$0.66$0.75$0.95$1.07$0.99$0.93$0.87-$5.89$0.83$0.60$0.04$1.20$0.64$1.08$0.53$1.31$1.62$1.05
Operating cash flow4,0573,8122,2613,6873,3062,9701,8874,7514,2522,8342,3265,5914,4391,9543,9176,3111,9741,1043,3934,181
Capital expenditure320253272247346278259342330284262324378260361320370347305344
Free cash flow3,7373,5591,9893,4402,9602,6921,6284,4093,9222,5502,0645,2674,0611,6943,5565,9911,6047573,0883,837
Buybacks2,7515,0000.07012,3002509054,0000.00.00.00.00.0n/an/an/an/an/an/an/a
Dividends paid1,0991,1851,1501,1541,1451,1961,1971,1911,1601,2121,2171,2161,2181,2581,2621,2631,2621,2831,2871,287
Shares outstanding2,180m2,129m2,135m2,126m2,099m2,101m2,089m2,035m2,022m2,027m2,027m2,028m2,029m2,035m2,035m2,036m2,036m2,042m2,043m2,044m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-K for the period ended 31 December 2021, filed 9 February 2022: the filing.